GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Operating Margin %

Apollon Formularies (AQSE:APOL) Operating Margin % : -839.58% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Apollon Formularies's Operating Income for the six months ended in Jun. 2023 was £-0.40 Mil. Apollon Formularies's Revenue for the six months ended in Jun. 2023 was £0.05 Mil. Therefore, Apollon Formularies's Operating Margin % for the quarter that ended in Jun. 2023 was -839.58%.

The historical rank and industry rank for Apollon Formularies's Operating Margin % or its related term are showing as below:

AQSE:APOL' s Operating Margin % Range Over the Past 10 Years
Min: -41100   Med: -245.11   Max: -3.14
Current: -839.58


AQSE:APOL's Operating Margin % is ranked worse than
94.79% of 1018 companies
in the Drug Manufacturers industry
Industry Median: 6.175 vs AQSE:APOL: -839.58

Apollon Formularies's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Apollon Formularies's Operating Income for the six months ended in Jun. 2023 was £-0.40 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.40 Mil.


Apollon Formularies Operating Margin % Historical Data

The historical data trend for Apollon Formularies's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Operating Margin % Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.14 -16.28 - - -384.85

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -215.15 -224.85 -839.58

Competitive Comparison of Apollon Formularies's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Operating Margin % falls into.



Apollon Formularies Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Apollon Formularies's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-0.762 / 0.198
=-384.85 %

Apollon Formularies's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-0.403 / 0.048
=-839.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollon Formularies  (AQSE:APOL) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Apollon Formularies Operating Margin % Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund Finds Only 2 Stocks Matching Their Criteria in Q1

By Holly LaFon Holly LaFon 04-10-2013

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013

Jeff Auxier Interview with GuruFocus

By Holly LaFon Holly LaFon 08-28-2012

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

Apollo Group Inc. Reports 10-Q Quarterly Operating Results

By gurufocus gurufocus 06-26-2012

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Update from FPA Capital - Seven Changes to Portfolio

By Sally Jones Sally Jones 07-14-2013